# q01 rev 1 raw returns (tested_sha256 dbae27b24ec253977887e482e7d1f02ff0b886d77e4042e0ca23494c8cf9fda5)

Fresh agents dispatched 2026-10-05 by the caller (Claude Code, Opus 5.5) with only the workspace
root, their own packet path and the verbatim question (closed-book: question only). Returns are
copied verbatim from the task notifications.

## Blind solver A (blind-solver, packet solver-1)

**answer:** −$0.15. The midpoint fell from $5.675 to $5.525.

**confidence:** high

**path:**
1. **When the deal closed.** D08 (Apr 16, 2026 release), line 27: "On March 23, 2026, Abbott completed its acquisition of Exact Sciences". D10 says the same at lines 203 and 685: "Exact Sciences was acquired by Abbott on March 23, 2026."
2. **Range in force on March 23, 2026.** This is the range issued Jan 22, 2026 (D07, lines 31 and 335): "Abbott projects full-year 2026 adjusted diluted earnings per share of $5.55 to $5.80". D07, line 33, still expected the deal "to close in the second quarter of 2026."
   - The next update came after the close. D08, line 15: "Updates Guidance to Reflect Acquisition of Exact Sciences". Line 223 gives "$5.38 to $5.58, which includes $0.20 of dilution related to the acquisition".
   - The packet has no document dated between Jan 22 and Apr 16, 2026.
3. **July 2026 range.** D10 (Jul 16, 2026), line 29: "Abbott raises full-year 2026 adjusted diluted EPS guidance range to $5.45 to $5.60, compared to previous range of $5.38 to $5.58". Line 329 repeats "$5.45 to $5.60."
4. **Calculation:**
   - January midpoint = (5.55 + 5.80) / 2 = 11.35 / 2 = 5.675
   - July midpoint = (5.45 + 5.60) / 2 = 11.05 / 2 = 5.525
   - Change = 5.525 − 5.675 = −0.150, which is **−$0.15** (already an exact cent).
5. **Check for other printed figures.** I searched the source docs/ files for every "$5.xx to $5.xx" range. Only three full-year 2026 ranges exist: $5.55–$5.80 (Jan), $5.38–$5.58 (Apr) and $5.45–$5.60 (Jul). All other hits are 2025 ranges.
6. **Consistency check.** The January midpoint minus the $0.20 deal dilution is 5.675 − 0.20 = 5.475, close to the April midpoint of 5.48.

**minimal_documents:** D07, D08, D10.
- D07 gives the January range.
- D10 gives the July range and also states the closing date.
- D08 dates the $5.38–$5.58 range to Apr 16, 2026, after the March 23 close. Without D08, D10's "previous range" cannot be dated. D08 also states the closing date, so either D08 or D10 covers that fact.
- No document in the rest of the packet can stand in for D07 or D08.

**readings:**
- **Alternative: start from the April range.** This treats the range "in force when it completed" the deal as the post-deal range: D10's "previous range" of $5.38–$5.58 (midpoint 5.48).
  - Change = 5.525 − 5.48 = +0.045. That rounds to +$0.05 (round half up) or +$0.04 (round half to even).
  - I reject this reading because that range was issued April 16, 2026, after the March 23 close. It was not in force at completion.
- **Primary answer stands:** −$0.15.

**gaps:**
- The packet has no Abbott document dated Jan 23 to Apr 15, 2026. So I cannot rule out, from documents, an interim guidance change at or before the close.
  - Nothing in D08 or D10 refers to any range other than $5.55–$5.80 → $5.38–$5.58 → $5.45–$5.60.
  - D08 does not itself say which range it replaced.
- **Coverage:**
  - **Read in full:** manifest, D09 (derivative settlement notice, no guidance) and D11 (NEC litigation release, no guidance).
  - **Read in part:**
    - D07: lines 1–60 and 325–354.
    - D08: lines 1–50 and 215–229.
    - D10: lines 1–45 and 320–335.
    - D06: lines 1–30. It is the company by-laws; a search found no guidance or $5.xx figures.
  - **Searched only:**
    - D01–D04: full-year 2025 releases.
    - D05: Nov 2025 deal announcement. It has no EPS dilution figure; the only accretion claim is to revenue growth and gross margin.
    - The financial tables and reconciliations in D07, D08 and D10.
  - The documents are plain text, so there were no PDF pages to check.

**contaminated:** no

Relevant files (all under `D:\Dev\Docket\tasks\aq-00745\runs\q01-r1-v2-dbae27b24ec253977887e482e7d1f02ff0b886d77e4042e0ca23494c8cf9fda5\solver-1\text\`):
- `D07.txt`
- `D08.txt`
- `D10.txt`

## Blind solver B (blind-solver, packet solver-2)

I did not read question.txt, the notes or any outside sources.

    answer: -$0.15 (the midpoint fell from $5.675 to $5.525)
    confidence: high
    path:
      1. Completion date: the acquisition closed on March 23, 2026. D08 (April 16, 2026 release), line 27: "On March 23, 2026, Abbott completed its acquisition of Exact Sciences". D10, line 49, gives the same date: "Exact Sciences, a cancer diagnostics company that Abbott acquired on March 23, 2026."
      2. Range in force on that date: Abbott issued it on Jan. 22, 2026. D07, line 31: "Abbott projects full-year 2026 adjusted diluted EPS of $5.55 to $5.80, which reflects growth of 10 percent at the midpoint." D07, line 335 (the guidance section) repeats it: "full-year 2026 adjusted diluted earnings per share of $5.55 to $5.80". D07, line 33, says Abbott still expected the deal "to close in the second quarter of 2026."
      3. Next update came after the completion date: D08 is dated April 16, 2026, and its headline (line 15) reads "Updates Guidance to Reflect Acquisition of Exact Sciences". Line 223 says: "full-year 2026 adjusted diluted earnings per share of $5.38 to $5.58, which includes $0.20 of dilution related to the acquisition of Exact Sciences." This range came out 24 days after closing, so it was not in force on March 23. No document in the packet shows a guidance change between Jan. 22 and April 16.
      4. July 2026 range: D10 (July 16, 2026), line 29: "Abbott raises full-year 2026 adjusted diluted EPS guidance range to $5.45 to $5.60, compared to previous range of $5.38 to $5.58." Line 329 repeats it: "$5.45 to $5.60."
      5. Calculation:
         - January midpoint = (5.55 + 5.80) / 2 = 11.35 / 2 = 5.675
         - July midpoint = (5.45 + 5.60) / 2 = 11.05 / 2 = 5.525
         - Change = 5.525 - 5.675 = -0.150, which is -$0.15. The result is exact, so rounding doesn't matter.
         - Check: 5.675 / 5.15 (2025 adjusted EPS, D07 line 27) = 1.102. That matches D07's "10 percent growth at the midpoint."
      6. I checked the figures against the original docs/ text files: abt_ex991_2026-01-22.txt lines 29 and 333, abt_ex991_2026-04-16.txt line 221, and abt_ex991_2026-07-16.txt lines 27 and 327. They all match.
    minimal_documents: D07, D08 and D10.
      - D07 gives the January range.
      - D08 dates the $5.38–$5.58 range to April 16, after the closing. Without it, D10's "previous range" could have been issued before March 23.
      - D10 gives the July range and also the March 23 completion date.
      - No other document can stand in for D08 in dating the intermediate range.
    readings:
      - Main reading: the range in force on March 23 is the January range, so the answer is -$0.15.
      - Alternative (I think it's wrong on the dates): treat the April 16 range ($5.38–$5.58, the first one that reflects the deal and the "previous range" D10 names) as the range in force at completion. The midpoint is 5.48, and 5.525 - 5.48 = +0.045. That is +$0.05 rounding half up, or +$0.04 rounding half to even. This reading ignores that the April range didn't exist on March 23.
      - The January range didn't include the $0.20 of Exact Sciences dilution that D08 mentions. The question asks for the change in the stated midpoint, so I made no adjustment.
    gaps:
      - The packet has no filing between Jan. 22 and April 16, 2026, so a reaffirmation or change outside the packet can't be ruled out. D08's "Updates Guidance" headline suggests April 16 was the first update.
      - What I read:
        - Read in full: D08, D09 (litigation settlement notice, not relevant) and D11 (formula litigation release, not relevant).
        - Read in part: D07 lines 1–60 and 325–354, and D10 lines 1–60 and 320–344.
        - D06 is the bylaws: I read only the header, and a search found no "2026", "guidance" or "earnings per share" in it.
        - D01–D05 were covered only by searches; they hold 2025 guidance and the November 2025 deal announcement, with no 2026 EPS range.
      - The packet has no layout files or PDFs (the manifest lists text extraction only), so I couldn't check any original pages. There were no extraction problems in the lines that matter.
    contaminated: no

## Closed-book solver (question only, no tools used)

answer: about −$0.20 (midpoint from $5.675 down to roughly $5.47–5.48). This is a guess, not a recalled figure.
confidence: low
basis: I recall that in January 2026 Abbott guided full-year 2026 adjusted diluted EPS of $5.55–$5.80, which excluded Exact Sciences; the midpoint is $5.675. I believe the deal closed around Q1 2026, so that range was likely still in force at closing. I don't know the July 2026 range because it falls after my knowledge cutoff. The figure assumes Abbott's earlier estimate that the deal would cut 2026 EPS by about $0.20, then folded into later guidance. I also don't know the exact closing date or whether the April update changed the range.
contaminated: no (only unrelated auto-attached account and environment details)

## Shortcut auditor (shortcut-auditor, packet shortcut)

answer: **−$0.15.** The midpoint fell from $5.675 to $5.525.

verdict: clear

shortest_path:
1. The deal closed on March 23, 2026. D08 line 27 says "On March 23, 2026, Abbott completed its acquisition of Exact Sciences". D10 lines 203 and 685 say the same.
2. The range in force on that date was the January 22, 2026 range. D07 line 31: "Abbott projects full-year 2026 adjusted diluted EPS of $5.55 to $5.80". Line 335 repeats it. D07 line 33 says the deal was still expected "to close in the second quarter of 2026", so this range was set before the close.
3. The next range came after the close. D08 is dated April 16, 2026 and is headlined "Updates Guidance to Reflect Acquisition of Exact Sciences". Its new range was "$5.38 to $5.58, which includes $0.20 of dilution related to the acquisition of Exact Sciences" (lines 15, 19 and 223). Because it was issued after March 23, it was not the range in force at completion.
4. The July range comes from D10, dated July 16, 2026. Line 29: "raises full-year 2026 adjusted diluted EPS guidance range to $5.45 to $5.60, compared to previous range of $5.38 to $5.58". Line 329 repeats it.
5. Calculation:
   - January midpoint: (5.55 + 5.80) / 2 = 5.675
   - July midpoint: (5.45 + 5.60) / 2 = 5.525
   - Change: 5.525 − 5.675 = −0.150, so −$0.15.

sufficient_documents: D07 + D08 + D10.
- D07 gives the January range.
- D10 gives the July range and the completion date.
- D08 is needed to show that D10's "previous range" ($5.38–$5.58) was issued on April 16, after the close. That rules it out as the range in force at completion. D08 also gives the completion date, as an alternative to D10.
- No single document has both the January and July ranges. D10 only compares July to the April range.

Difficulty risk: this is a simple three-document join with easy arithmetic. A reader who assumes guidance only changes with quarterly results might skip D08 and use just D07 + D10. That is a difficulty risk, not a shortcut.

searches:
- **Terms searched:**
  - "Exact Sciences" (found in D05, D07, D08 and D10)
  - completed/closed acquisition
  - guidance, projects, outlook and EPS / earnings per share
  - every "$x.xx to $x.xx" range
  - previous, prior, initial, reaffirm, raise, narrow and update near guidance or range
  - "5.55", "5.80", "midpoint", "0.15", "0.20" and "excluding Exact" in D08 and D10 (no January range restated, no midpoint statement)
  - "2026" in D01–D04 (no 2026 EPS guidance)
  - dilution and accretion in D05 and D06
- **Inspected:**
  - D07, D08 and D10: headers and guidance sections read.
  - D05 (Nov 20, 2025 deal announcement): close expected in Q2 2026, no EPS guidance.
  - D06: amended by-laws.
  - D09: derivative settlement notice.
  - D11: NEC litigation settlement.
  - D01–D04: these contain only 2025 guidance.
- **Original files:** I checked all three ranges and the completion date against the files in docs/; they match the extracted text exactly.

readings/gaps:
- **Trap reading:** using D10's "previous range" of $5.38–$5.58 (midpoint $5.48) gives 5.525 − 5.48 = +0.045. That rounds to +$0.05, or +$0.04 under round-half-even. I rejected it because that range was issued on April 16, after the March 23 close.
- **Not asked:** the January-to-April change is −$0.195, about −$0.20, which matches the stated $0.20 dilution.
- **Gap:** the packet has no filings between January 22 and April 16, 2026. An interim guidance change outside the packet, such as a closing-day 8-K, can't be ruled out. However, D08's "Updates Guidance to Reflect Acquisition" headline and D07's expectation of a Q2 close both support the January range still being in force on March 23.
- **Rounding:** −0.150 is exact, so there is no rounding ambiguity.

Files:
- D:\Dev\Docket\tasks\aq-00745\runs\q01-r1-v2-dbae27b24ec253977887e482e7d1f02ff0b886d77e4042e0ca23494c8cf9fda5\shortcut\text\D07.txt
- D:\Dev\Docket\tasks\aq-00745\runs\q01-r1-v2-dbae27b24ec253977887e482e7d1f02ff0b886d77e4042e0ca23494c8cf9fda5\shortcut\text\D08.txt
- D:\Dev\Docket\tasks\aq-00745\runs\q01-r1-v2-dbae27b24ec253977887e482e7d1f02ff0b886d77e4042e0ca23494c8cf9fda5\shortcut\text\D10.txt
- D:\Dev\Docket\tasks\aq-00745\runs\q01-r1-v2-dbae27b24ec253977887e482e7d1f02ff0b886d77e4042e0ca23494c8cf9fda5\shortcut\docs\abt_ex991_2026-01-22.txt
- D:\Dev\Docket\tasks\aq-00745\runs\q01-r1-v2-dbae27b24ec253977887e482e7d1f02ff0b886d77e4042e0ca23494c8cf9fda5\shortcut\docs\abt_ex991_2026-04-16.txt
- D:\Dev\Docket\tasks\aq-00745\runs\q01-r1-v2-dbae27b24ec253977887e482e7d1f02ff0b886d77e4042e0ca23494c8cf9fda5\shortcut\docs\abt_ex991_2026-07-16.txt
